Beyond Aducanumab: Neurimmune Advances Portfolio Of Clinical Candidates

The Swiss firm that discovered Biogen’s Alzheimer’s therapy aducanumab has built a pipeline of clinical programs across neurological and other diseases and may seek additional partners as candidates advance.

Signpost outside is showing Phase 1 and Phase 2
Neurimmune is transitioning from a Phase I to a Phase II company • Source: Shutterstock

Neurimmune AG is stepping out from behind the long shadow of its best-known therapeutic candidate – the amyloid-beta-targeting aducanumab for Alzheimer’s disease, which Biogen intends to submit for US Food and Drug Administration approval any day now. The Swiss company has begun to more prominently showcase its growing clinical pipeline and may seek external partners as later-stage programs achieve proof-of-concept to fund its ongoing drug discovery work.

Zurich-based Neurimmune, with just 50 employees, recently took its sixth antibody candidate into clinical trials, enrolling the first patient in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.